Trimodal Therapy Appears Equivalent to Radical Cystectomy for Select MIBC Patients
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
New findings could inform personalized therapeutic strategies for patients with renal cell carcinoma, according to investigators.
The median progression-free survival was similar between the treatment arms.
The immunotherapy N-803 appears to boost innate immune memory and prolong the duration of response to therapy.
The study’s primary endpoint was met, and neoadjuvant chemotherapy was considered well tolerated.
Bone loss was observed in both treatment arms, but abiraterone plus prednisone did not increase bone loss.
By blinded independent review, there was a 39% reduction in the risk of progression or death with olaparib.
Compared with German and US patients, UK patients were less likely to be diagnosed with prostate cancer via routine screening.
Adding darolutamide to ADT and docetaxel improves overall survival in patients with metastatic hormone-sensitive prostate cancer.
Men of African ancestry had the highest risk of developing metastatic prostate cancer when compared with men of other ancestries.